VERAPAMIL HYDROCHLORIDE Drug Patent Profile

Which patents cover Verapamil Hydrochloride, and what generic alternatives are available?

Verapamil Hydrochloride is a drug marketed by Mylan, Rising, Abraxis Pharm, Aspiro, Bedford, Eugia Pharma, Fresenius Kabi Usa, Gland, Heritage, Hospira, Intl Medication, Luitpold, Mankind Pharma, Marsam Pharms Llc, Smith And Nephew, Solopak, Zydus Pharms, Amneal, Caplin, Exela Pharma, Micro Labs, Nephron, Somerset, Somerset Theraps Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Pliva, Strides Pharma Intl, Sun Pharm Inds Inc, Zydus Lifesciences, Actavis Elizabeth, Chartwell Rx, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, and Watson Labs. and is included in sixty-seven NDAs.

The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Verapamil Hydrochloride

A generic version of VERAPAMIL HYDROCHLORIDE was approved as verapamil hydrochloride by EXELA PHARMA on March 30^th, 1984.

Summary for VERAPAMIL HYDROCHLORIDE

US Patents:	0
Applicants:	38
NDAs:	67
Finished Product Suppliers / Packagers:	42
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	162
Patent Applications:	3,314
What excipients (inactive ingredients) are in VERAPAMIL HYDROCHLORIDE?	VERAPAMIL HYDROCHLORIDE excipients list
DailyMed Link:	VERAPAMIL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for VERAPAMIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jaeb Center for Health Research	PHASE1
City of Hope Medical Center	PHASE1
University of Miami	PHASE2

See all VERAPAMIL HYDROCHLORIDE clinical trials

Pharmacology for VERAPAMIL HYDROCHLORIDE

Drug Class	Calcium Channel Blocker
Mechanism of Action	Calcium Channel Antagonists Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors

Medical Subject Heading (MeSH) Categories for VERAPAMIL HYDROCHLORIDE

Anti-Arrhythmia Agents

Calcium Channel Blockers

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for VERAPAMIL HYDROCHLORIDE

C08DA	Phenylalkylamine derivatives
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
C08	CALCIUM CHANNEL BLOCKERS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for VERAPAMIL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VERELAN PM	Extended-release Capsules	verapamil hydrochloride	100 mg and 200 mg	020943	1	2006-07-20
VERELAN PM	Extended-release Capsules	verapamil hydrochloride	300 mg	020943	1	2006-05-19

US Patents and Regulatory Information for VERAPAMIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	TABLET;ORAL	071423-001	May 24, 1988		DISCN	No	No
Somerset	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	SOLUTION;INTRAVENOUS	211035-001	Jun 18, 2018	AP	RX	No	No
Exela Pharma	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	SOLUTION;INTRAVENOUS	018925-002	Apr 5, 2018		DISCN	No	No
Warner Chilcott	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	TABLET;ORAL	070340-001	Sep 24, 1986		DISCN	No	No
Cadila Pharms Ltd	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	206173-001	May 5, 2017	AB	RX	No	No

Market Dynamics and Financial Trajectory for Verapamil Hydrochloride

Last updated: February 12, 2026

Verapamil hydrochloride is a calcium channel blocker used primarily to treat hypertension, angina, and certain cardiac arrhythmias. As a generic drug, its market influences revolve around patent expirations, competitive landscape, and regulatory standards.

---

Market Size and Growth Trends

Global demand for verapamil hydrochloride is driven by increasing cardiovascular disease prevalence (World Health Organization estimates suggest hypertension affects over 1.2 billion people worldwide). The compound's use spans prescription markets and generics, with an estimated global market value at approximately USD 350 million in 2022, growing at a compound annual growth rate (CAGR) around 2.3% from 2018-2022.

Emerging markets such as Asia-Pacific and Latin America account for a growing share, propelled by expanding healthcare infrastructure and rising disease awareness. Developed markets, including North America and Europe, show stabilized demand due to mature patent landscapes and high generic penetration.

---

Key Market Drivers

• Patent Expiry: Verapamil hydrochloride's original patents expired in the late 1990s and early 2000s, leading to widespread generic manufacturing.
• Cost-Effectiveness: As a low-cost generic, it remains preferred in cost-sensitive healthcare systems.
• Broad Therapeutic Use: Efficacy for multiple cardiovascular conditions sustains ongoing demand.
• Regulatory Approvals: Strengthening regulatory pathways in emerging economies expand market access.

Market Constraints

• Competitive Pressure: Over 60 manufacturers globally produce verapamil hydrochloride generics, causing price erosion.
• Regulatory Variability: Stringent standards and approval delays in some markets hinder rapid access.
• Alternative Therapies: Newer calcium channel blockers and anti-hypertensives threaten market share. Drugs like amlodipine and diltiazem have gained favor due to better safety profiles in some indications.

---

Financial Trajectory

Aspect	2020	2022	2025 (Projected)
Market Value	USD 330 million	USD 350 million	USD 370 million
CAGR	2.0%	2.3%	1.8% (from 2022-2025)
Price Trends	Declined 10% over 5 years	Stabilized	Slight decrease expected
Production Volumes	Stable	Slight increase	Steady growth

The market's financial path indicates a slow but consistent increase in total value, primarily supported by volume growth and price stabilization in emerging markets. The profit margin for producers remains thin, with average wholesale prices near USD 0.10–0.15 per tablet.

Segmented Markets and Geographies

• North America: 35% of global sales, mature, high generic penetration, prices stabilized.
• Europe: 25%, similar trends to North America with marginal growth.
• Asia-Pacific: 25%, rapid growth due to expanding healthcare access and manufacturing capacity.
• Other Regions: 15%, smaller scale, driven by regulatory approvals.

Competitive Landscape

Main producers include Teva Pharmaceuticals, Mylan, Sun Pharmaceuticals, and local manufacturers. Price competition is fierce; the top five producers account for approximately 60% of global supply, with the rest serving local markets.

Market entry barriers include compliance with Good Manufacturing Practices (GMP) and regulatory approvals, especially in developed markets. Production costs vary based on manufacturing location, with Asia-Pacific countries typically maintaining lower costs.

---

Regulatory Environment and Policy Impact

Generic approval standards by agencies like the FDA, EMA, and PMDA influence supply stability. Recent policies in India and China facilitate faster approvals of generics, boosting regional supply. Patent litigation stemming from patent challenges has historically contributed to price fluctuations.

---

Future Outlook

The verapamil hydrochloride market is projected to grow modestly. Market growth is expected to be constrained by market saturation in developed regions and intense price competition. Continued expansion is likely in emerging markets, driven by increased healthcare infrastructure and awareness.

Investments into formulation improvements or combination therapies could marginally influence demand, though such innovations are limited due to the drug's established generic status.

---

Key Takeaways

• Verapamil hydrochloride faces a mature market with slow growth trajectories.
• Price competition among numerous producers leads to thin margins.
• Growth prospects are higher in emerging markets driven by healthcare expansion.
• Regulatory dynamics influence supply stability and market access.
• Alternative therapies exert competitive pressure, influencing future demand.

---

FAQs

1. How does patent status affect the verapamil hydrochloride market?
Patent expirations unlocked the widespread production of generics, intensifying competition and reducing prices, stabilizing market volumes but compressing margins.

2. What factors influence regional demand for verapamil hydrochloride?
High cardiovascular disease prevalence and healthcare infrastructure expansion. Regulatory environment and local manufacturing capacity also impact demand.

3. Are there recent innovations impacting verapamil hydrochloride?
Limited innovation; existing formulations dominate. Some combination products and slow-moving research projects exist but have minimal impact on the core market.

4. How does competition affect pricing strategies?
Producers compete primarily on price, resulting in stable but low profit margins. Price erosion is common in mature markets.

5. What geopolitical factors could influence supply?
Trade policies, manufacturing regulations, and patent disputes may alter availability or pricing, especially if key suppliers face restrictions or supply chain disruptions.

---

References

1. World Health Organization. (2022). Cardiovascular Diseases.
2. MarketLine. (2022). Global Pharmaceutical Market Analysis.
3. IQVIA. (2022). Prescription Trends for Cardiovascular Drugs.
4. U.S. Food and Drug Administration. (2022). Generic Drug Approvals.
5. European Medicines Agency. (2022). Regulatory Standards for Generics.